The analyst landscape is thin but uniformly bullish. Three firms maintain Buy ratings: Chardan Capital (analyst Geulah Livshits) reiterated a $12 target in May 2026, citing a "strengthened clinical, regulatory, and financial position"; H.C. Wainwright has maintained a $12 target; and Leerink Partners initiated coverage with a lower $6 target in November 2025, acknowledging "promising potential" in SENTI-202 while flagging financial risk. A fourth, older $15 target from Laidlaw & Co. (June 2025) was excluded as stale.
These targets pre-date the 1-for-33 reverse stock split that took effect November 18–19, 2026. Because a reverse split changes the share count without changing company value, the pre-split figures must be multiplied by 33 to compare against today's post-split price. That yields a split-adjusted range of roughly $198 to $396 and a calculated mean of $330. This is a mathematically derived average of the verified targets above the current price — not an official published consensus, and not a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Senti Bio closed near $1.77 on November 20, 2026, in the first sessions after the reverse split, down sharply from the split-adjusted opening level. The required move to $330 is a very large — indeed extraordinary — percentage gain, on the order of 18,500%. This reflects a company valued at only about $4.6 million in market capitalization, versus an implied target valuation approaching $850 million. The path toward any such re-rating runs through positive SENTI-202 Phase 1 data in AML, additional pipeline validation, and securing the capital to keep the program alive. From what I see, the post-split trading behavior reinforces how sensitive the share price remains to any new developments.
The bull case rests on SENTI-202, a logic-gated, off-the-shelf CAR-NK therapy targeting AML, a blood cancer with substantial unmet need. Favorable Phase 1 safety or efficacy signals could trigger a sharp re-rating of a stock with so few shares outstanding. The Gene Circuit platform also has partnered programs, and every covering analyst currently rates the stock a Buy. A successful financing on improved terms would remove an immediate overhang and could support the SNTI stock forecast.
The risks are severe. Senti Bio reported roughly $5.5 million in cash against a trailing net loss of about $43 million, meaning the company likely needs to raise capital soon — raising the prospect of dilution that would push any per-share target lower. The 1-for-33 reverse split was undertaken specifically to cure a Nasdaq minimum bid-price deficiency, a classic sign of financial distress. Early-stage cell therapies carry high clinical failure rates, and a setback in SENTI-202 would likely remove the core thesis. Even modest market skepticism could keep the stock far below the analyst price target.
Technical structure is resetting in the wake of the reverse split. The stock fell from a split-adjusted open near $2.97 to around $1.77, with the November 20 low near $1.71 acting as initial support. Resistance sits at the recent split-adjusted high near $2.79–$2.97, and the $1.00 level is both psychological and regulatory — Nasdaq requires a sustained bid above $1.00 for continued listing. With so little trading history post-split, these levels are fragile and should be treated cautiously. One thing that stands out after reviewing the post-split action is how quickly support levels can shift in names like this.
Analyst price targets generally reflect a research horizon of about 12 months, though the covering firms have not published explicit timelines and their assumptions may differ. The key items to watch are SENTI-202 Phase 1 data updates, any new financing or dilution, cash-burn disclosures in quarterly filings, Nasdaq listing-compliance status, and any target revisions from Chardan, H.C. Wainwright, or Leerink. These catalysts, rather than the current market price alone, will determine whether the target is realistic. I’m watching this closely as new data emerges.
In my own research, Tickeron's AI Daily Buy/Sell Signals help me monitor volatile names like this by generating Buy, Sell, or Hold signals based on changing market conditions and technical behavior. For an event-driven stock such as Senti Bio, the tool surfaces opportunities and trend shifts more efficiently than manual screening alone, which complements my fundamental work without replacing it.
The $330 target is a split-adjusted average of three analyst price targets — not a forecast, and not an official consensus. It requires a move of roughly 18,500% from the current price near $1.77, which is an extraordinary ask that only makes sense in the context of a sub-$5 million micro-cap whose fate depends on a single Phase 1 asset. The strongest support is the unanimously bullish analyst view and the AML opportunity; the principal obstacles are a dwindling cash position, likely dilution, clinical uncertainty, and the distress signaled by the recent reverse split. Investors should monitor SENTI-202 data and the company's financing plans above all, and should treat any per-share target here with exceptional skepticism.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SNTI declined for three days, in 274 of 311 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for SNTI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 39 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
The Aroon Indicator for SNTI entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.596). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology